Open an account

Monte Rosa Therapeutics

GLUE · NASDAQ

$11.36+$0.70 (+6.57%)TodayMarket closed ·
Prev close $10.66

About GLUE

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company is headquartered in Boston, Massachusetts and currently employs 150 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Employees
150
Headquarters
Boston, Massachusetts
Listed
Jun 24, 2021
Sector
Health Care
Industry
Biotechnology
Website
monterosatx.com

GLUE key statistics

Market cap
969.16M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.51M
Volume
1.86M
Open price
$10.72
High today
$11.42
Low today
$10.56
52 Week high
$25.77
52 Week low
$8.94

Monte Rosa Therapeutics (GLUE) at a glance

Monte Rosa Therapeutics (GLUE) last traded at $11.36, with a market cap of 969.16M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.56 and $11.42. The current price is 7.6% above the day's low and 0.5% below its high.

Volume so far is 1.86M shares, above the average of 1.51M shares a day.

Over the past year Monte Rosa Therapeutics has ranged from $8.94 to $25.77, and now sits 14% of the way up that range.

Monte Rosa Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.43 per share against an estimate of -$0.3888.

The average analyst price target is $29.38, 158.6% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 8 analystsAvg $29.38
Low
$25.25
Now
$11.36
High
$38.85

GLUE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 291.7% on average.

  1. Q3 FY24: reported -$0.29 per share against an estimate of -$0.4962
  2. Q4 FY24: reported $0.23 per share against an estimate of -$0.0235
  3. Q1 FY25: reported $0.56 per share against an estimate of -$0.3437
  4. Q2 FY25: reported -$0.15 per share against an estimate of -$0.3934
  5. Q3 FY25: reported -$0.33 per share against an estimate of -$0.3802
  6. Q4 FY25: reported -$0.56 per share against an estimate of -$0.3586
  7. Q1 FY26: reported -$0.45 per share against an estimate of -$0.3876
  8. Q2 FY26: reported -$0.43 per share against an estimate of -$0.3888

GLUE news

  • Vandana Singh

    Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease

  • Mohd Haider

    GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge?

  • Press releaseGlobe Newswire

    Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Press releaseGlobe Newswire

    Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

  • 10 Health Care Stocks Whale Activity In Today's Session

  • Press releaseGlobe Newswire

    Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

  • Avi Kapoor

    Crude Oil Down 2%; ISM Services PMI Surges In December

Similar companies

Companies in the same industry as Monte Rosa Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.